Introduction: We aimed to characterize current practice patterns among endourologists on medical expulsive therapy (MET) for treatment of ureteral calculi. Methods: An online survey was administered to Endourological Society members. Respondents' MET usage, index case management, and awareness of recent guidelines and literature were compared based on international status, practice setting, interval since training, and endourological fellowship training. Results: Of the 237 complete responses, 65% were international, 61% were academic, 66% had >10 years in practice, and 71% were endourology fellowship-trained. MET was used by 88%, with no differences between international, academic, practice length, and fellowshiptrained groups. MET was used more frequently for <8 mm and distal stones and more U.S.-based respondents reported use for proximal/midureteral stones (68% vs 43%; p<0.001). For the index patient, 70% preferred MET as the initial approach and respondents <10 years from training were more likely to choose MET (82% vs. 64%; p=0.006). While 82% of respondents were aware of the SUSPEND trial, 70% reported that it had not altered their use of MET. Current American Urological Association (AUA) guideline awareness was 90%. Mean MET prescription length was 19.9±10.3 days, and was statistically significantly longer for respondents who were U.S.-based, academic and <10 years from training. Conclusions: MET is the preferred approach for patients with ureteral calculi <10 mm among endourologists despite conflicting data in the literature. While current AUA practice guidelines are followed by the majority of respondents, our survey suggests MET is being used more liberally than the guideline criteria, specifically in proximal and midureteral stones.
Introduction
Medical expulsive therapy (MET) is a frequently utilized approach in the management of ureteral calculi. Although it is a recommended initial option per the current AUA guidelines, recent studies have challenged this paradigm. 1 The Pickard et al. (SUSPEND) and Furyk et al. trials were two large multicenter, randomized controlled trials published in 2015 that found spontaneous passage rate of ureteral stones to be similar for patients prescribed MET compared to placebo. 2, 3 Current American Urological Association (AUA) guidelines published in May 2016 recommend MET only for patients with distal ureteral stones ≤10mm while the European Association of Urology (EAU) guidelines recommend use for all ureteral stones. 1, 4 Furyk et al. also found that MET increased the likelihood of spontaneous stone passage in a subset of larger stones 5-10mm in size (p=0.03). 3 A recent systematic meta-analysis of MET studies by Hollingsworth et al. included both SUSPEND and Furyk data and concluded that MET increased the likelihood of stone passage for stones ≥5mm, regardless of location. 5 The conflicting data in the above studies and guidelines has generated some doubt about the efficacy of MET. Given the context of recent challenges, we sought to characterize current practice patterns and perspectives on MET for the treatment of ureteral calculi among members of the endourological society. A better understanding of current practice patterns, knowledge of the literature and attitudes with regards to MET among practicing urologists could help determine the need for further studies and improve evidence based education on the initial management of ureteral calculi.
Methods
An online survey was designed and administered to members of the Endourological Society in August and September of 2016 via the REDCap platform hosted at the Cleveland Clinic Foundation. 6 Study data was collected and managed using REDCap's electronic data capture tools. Consisting of 22 questions, the survey included an index case that served as the basis for a series of management options. The index case was described as a patient "presenting with ureteral calculi ≤10mm, adequately controlled pain, and without fever" (Full survey in supplemental data). Additionally, we captured other metrics including demographics, international status, type of practice, interval since training completion, fellowship training in endourology, as well as individual perspectives and knowledge on MET. Using email addresses in the Endourological Society's member database, the survey was sent twice to 2,815 recipients spaced two weeks apart. Responses were recorded and anonymized automatically through the REDCap system and surveys were eliminated from statistical analysis if ≤14 questions were unanswered (i.e. the equivalent of stopping after the first page). MET usage and index case management were evaluated based on respondents' international status, practice setting, interval since training completion, and fellowship training. Statistical analysis was performed via Pearson chi-square, Fisher's
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Results
Two hundred and thirty-seven completed responses were received with 285 surveys being opened but not completed beyond the first page of the survey, giving a completion rate of 83%. Of the completed responses 65% were international, 61% were academic urologists, 66% had >10 years in practice, and 71% were fellowship-trained in endourology (Full demographic data supplemental data). The majority of respondents (88%) reported using MET for patients with ureteral calculi with no significant differences between the international, academic, practice length, and fellowship trained groups (Table 1 ). For the index patient MET was the preferred initial approach for 70% of respondents, followed by observation in 14%, and surgical options (URS, SWL, and stent placement) in 16%. Respondents within 10 years of training were significantly more likely to choose MET (82% vs 64%, p=0.006, Table 1 ).
Overall, 82% percent of respondents reported being aware of the results of the SUSPEND trial, with higher awareness among urologists from the US (89% vs 78%, p=0.043, Table 1 ), those with endourology fellowship training (86% vs 75%, p=0.038), and those in academic practice (89% vs 72%, p=0.001). Although awareness was high, 70% of respondents reported that the results had not altered their use of MET. Additionally, 90% reported being aware of the current AUA guidelines on the surgical management of stones with no significant variation based on duration of practice or academic practice setting (Table 1) .
Mean MET prescription length was 19.9 ± 10.3 days for all respondents and 37% prescribed MET for ≥28 days, the prescription length used in the SUSPEND and Furyk et al. trials.
2,3 MET prescriptions were significantly longer for respondents who were US-based (22.9 vs 18.1 days, p=0.001, Table 1 ), in academic settings (22.3 vs 16.1 days, p<0.001), and within 10 years of training (23.9 vs 17.7 days, p<0.001).
Respondents utilized MET more often for distal stones as compared to mid-ureter or proximal stones (98% vs 59% vs 44% respectively, Table 2 ). For stones sized 5-8mm, 8-10mm, and >10mm, 76%, 33% and 8% of respondents reported using MET, respectively ( Table 2) . US-based respondents were more likely to use MET for proximal and midureteral stones (68% vs 43%, p<0.001, Table 3 ) as well as for stones >10mm (13% vs 4%, p=0.009). Twenty-nine percent of respondents reported that they would prescribe MET to pregnant patients with ureteral calculi and 18% reported that they were unsure or would defer to an obstetrician with no significant variations based on academic practice setting (Table 4) .
US-based respondents within 10 years of training were more likely to agree that additional education of emergency department physicians on MET is necessary (94% vs 76%, p=0.033). Respondents in academic settings were significantly less likely to report an ED to clinic follow-up time of less than 1 week (58% vs 81%, p<0.001, Table 4 ).
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The criteria for the initiation and use of MET have been the subject of debate in the urologic community, given the discordance in data from several studies. We evaluated real world utilization of MET as well as the awareness and impact of relevant literature and guidelines amongst endourologists.
Our results suggest that the majority of endourologists prefer MET as an initial approach to managing ureteral calculi. This trend is consistent across duration, location, and type of practice as well as endourological fellowship training. Interestingly, our rate of MET usage was slightly lower than a survey by Lloyd et al. (88.4% vs 99.6%) which collected data ending in June of 2015, just prior to the publication of the SUSPEND trial. 7 This could be attributed to a decline in MET usage based on data refuting its efficacy, or perhaps this reflects an overall higher utilization in a broader survey target group which included both endourologists and general urologists. Another finding in our survey is that few endourologists (29%) report use of MET in pregnant patients. Lloyd et al. showed a similar trend and further elucidated that concern of legal risk and patient safety contributed significantly to physician nonuse of MET during pregnancy. 7 Nonetheless, recent evidence has emerged regarding the safety of using tamsulosin in pregnant females, while the FDA continues to class tamsulosin as category B, indicating no evidence of fetal harm shown in animal studies. 8 Respondents with specific endourology fellowship training did not prescribe MET more often than their non-fellowship trained counterparts, but were more likely to report being aware of the current literature. The current AUA guidelines only recommend MET for patients with distal stones <10mm in size and the EAU recommends MET for all ureteral stones. 1, 4 However, it is foreseeable that future guidelines will continue to evolve to factor in the results from the SUSPEND trial and other future large scale RCTs. 9 Of our US respondents, 13% used MET for stones >10mm in size and 68% used MET for stones in the proximal or mid ureter. This reflects a deviation from the AUA guidelines, and is a significantly higher rate than international respondents. Adherence to the AUA guidelines as measured by MET usage in stones >10mm or in the proximal/mid ureter, was not significantly impacted by either endourology fellowship training or interval from training (Table 3) . It is important to note that at the time the survey was administered, the new AUA guidelines had been in place for only 4 months. 1 It is possible that some of the reported use of MET beyond the scope of the AUA guidelines is due to physicians not being aware of the new guidelines or are following the EAU guidelines, but these are not conclusions we can draw from our study design. A recent patient questionnaire by Bell et al. found that 49% of patients would try tamsulosin after being given a summary of the conflicting data for MET and 25% were unsure; 71% preferred trying medical therapy before pursuing surgical options. 10 It appears that both patient and physician preferences do not currently reflect recent prospective
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Fedrigon et al Use of medical expulsive therapy evidence, as evidenced by our finding that 70% of endourologists have not changed their usage of MET in response to the recent trials. In addition, with nearly half of patients willing to try MET despite recent evidence based on the Bell et al. results and 85% of our respondents recommending more research on MET, it will be important to disseminate future literature findings to both patients and physicians to aid in clinical recommendations.
There appears to be some disparity between the available evidence on MET and the current guidelines. Additionally, our data suggests expanded use of MET beyond the criteria set by the guidelines. Both of these trends indicate that practice patterns and patient care could benefit from clear guidelines backed by more conclusive literature on the use and efficacy of MET. Better tools for the translation of both current guidelines and recent literature findings to physicians might become a future clinical priority when a consensus on the use of MET is reached.
This report highlights the current trends and preferences among endourologists regarding MET and management of ureteral stones. One limitation of our study is that the survey design limits our abilities to draw conclusions regarding underlying explanations for the observed trends. Additionally, since our sample consisted of practicing Endourological Society members, our respondent population is unique in their expertise with endourology and stone disease, which may limit our ability to generalize the observed trends to the wider community of practicing urologists.
The completion rate for opened surveys was 83% and a total of 237 responses were recorded from the 2,815 Endourological Society members contacted. For comparison, Lloyd et al. did not record a response rate but received 537 responses from surveys sent to mailing lists from the regional sections of the AUA as well as the Endourological Society. Considering this our response rate and total number of completed surveys seems adequate given only the Endourological Society was used for our survey and the number of opened surveys could have been impacted by inactive or outdated emails.
While the AUA or EAU guidelines do not specify length of MET, our data showed an average usage of MET for 19.9 ± 10.3 days, which is shorter than the duration of 28 days examined in large recent scale trials. 2, 3 Respondents in the US, in academic settings, and with an interval from training of less than 10 years all had significantly longer prescription lengths for MET. With regards to our index patient, the majority of respondents preferred MET as the initial approach, followed by observation and surgical intervention. Interestingly, urologists within 10 years of training were significantly more likely to choose MET. Respondents in academic practice settings were significantly less likely to report a clinic follow-up time after initial ED encounter of less than 1 week. Although we did not elucidate the causality of this in our survey, it is possible that less available clinic time and longer duration of prescribed MET in an academic practice necessarily pushes back followup appointments to a later time.
Of our respondent population, 82% reported aware of the controversy surrounding the SUSPEND trial results. Significantly, 70% reported that this had not changed their practice
Fedrigon et al Use of medical expulsive therapy regarding MET. This may be a reflection of endourologists awaiting more convincing evidence before changing established practice. It will be interesting to observe the evolution of the use of MET as more data emerges and as the guidelines are updated in the future.
A previous study at our institution estimated that half of ED patients who met criteria for MET did not receive it. 11 There was a consensus among our respondents that more education of ED personnel is necessary to standardize prescription and usage of MET, suggesting that this might be a commonly encountered issue for our respondents. Additionally, nearly 85% of respondents recommended more research on MET. In light of this, we have developed a standardized stone care protocol in conjunction with ED physicians for patients with renal colic.
Conclusion
Medical expulsive therapy continues to be the preferred initial approach for patients with ureteral calculi <10mm among endourologists despite conflicting data in the literature. While the current AUA practice guidelines are followed by the majority of respondents, it is notable that our survey suggests MET is being used more liberally than the criteria established in the guidelines, specifically in proximal and mid ureteral stones. Use of medical expulsive therapy
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